Trial Profile
A Prospective, Observational, International, Multi-center Study to Measure the Relationship Between Relapse and Adherence in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Rebismart 2.0 + MSdialog, Assessing Quality of Life
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ADHERQOL
- Sponsors Merck KGaA
- 22 Apr 2016 Status changed from recruiting to discontinued because of lower than anticipated recruitment rate.
- 23 Mar 2015 New trial record